Epidermal growth factor (EGF) is a potent mitogen which elicits a variety of short and long term changes in its target cells, culminating in the stimulation of cellular proliferation. EGF produces its effects initially by activation of the intrinsic tyrosine kinase activity of the EGF receptor. The specific biological effects of EGF are presumed to be mediated by serial activation of other enzymes, including protein kinases. We have discovered a serine-threonine kinase which is rapidly and tran- siently activated on exposure of A431 cells to EGF. This enzyme phosphorylates the microtubule associated protein MAP2. We propose to investigate whether the activation of the MAP2 kinase is mediated through phosphorylation of the enzyme by the EGF receptor or C-kinase. The activity of the EGF-R kinase is regulated by phosphorylation at serine and threonine residues, thus, we will ascertain if MAP2 kinase mediates these effects. The MAP2 kinase has been purified to near homogeneity. We propose to scale up the purification in order to obtain amino acid sequence data. Amino acid sequence data will permit syn-thesis of oligonucleotides for use in cloning and sequencing the gene. The biological function of the MAP2 kinase will be inves-tigated through creation of protein-specific hypomorphic or null mutants deficient in MAP2 kinase. This will be accomplished by introduction antisense oligonucleotides complementary to MAP2 mRNA into cells. We will determine if deletion of this protein kinase alters the responsiveness of the cells to EGF. The MAP2 kinase phosphorylates a c-Fos related peptide, suggesting that the kinase may meditate the transcriptional activation of EGF-regulated genes. The ability of MAP2 kinase to phosphorylate trans-acting transcriptional regulators will be investigated.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM034908-05
Application #
3286775
Study Section
Cellular Biology and Physiology Subcommittee 1 (CBY)
Project Start
1986-07-01
Project End
1993-06-30
Budget Start
1991-07-01
Budget End
1992-06-30
Support Year
5
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Taylor, L K; Swanson, K D; Kerigan, J et al. (1994) Isolation and characterization of a nerve growth factor-regulated Fos kinase from PC12 cells. J Biol Chem 269:308-18
Myers, M P; Murphy, M B; Landreth, G (1994) The dual-specificity CLK kinase induces neuronal differentiation of PC12 cells. Mol Cell Biol 14:6954-61
Taylor, L K; Marshak, D R; Landreth, G E (1993) Identification of a nerve growth factor- and epidermal growth factor-regulated protein kinase that phosphorylates the protooncogene product c-Fos. Proc Natl Acad Sci U S A 90:368-72
Jaiswal, R K; Murphy, M B; Landreth, G E (1993) Identification and characterization of a nerve growth factor-stimulated mitogen-activated protein kinase activator in PC12 cells. J Biol Chem 268:7055-63
Roy, L M; Gittinger, C K; Landreth, G E (1991) Epidermal growth factor treatment of A431 cells alters the binding capacity and electrophoretic mobility of the cytoskeletally associated epidermal growth factor receptor. J Cell Physiol 146:63-72
Schanen-King, C; Nel, A; Williams, L K et al. (1991) Nerve growth factor stimulates the tyrosine phosphorylation of MAP2 kinase in PC12 cells. Neuron 6:915-22
Nel, A E; Hanekom, C; Rheeder, A et al. (1990) Stimulation of MAP-2 kinase activity in T lymphocytes by anti-CD3 or anti-Ti monoclonal antibody is partially dependent on protein kinase C. J Immunol 144:2683-9
Roy, L M; Gittinger, C K; Landreth, G E (1989) Characterization of the epidermal growth factor receptor associated with cytoskeletons of A431 cells. J Cell Physiol 140:295-304
Hanekom, C; Nel, A; Gittinger, C et al. (1989) Complexing of the CD-3 subunit by a monoclonal antibody activates a microtubule-associated protein 2 (MAP-2) serine kinase in Jurkat cells. Biochem J 262:449-56